vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and IMAX CORP (IMAX). Click either name above to swap in a different company.
COLLEGIUM PHARMACEUTICAL, INC is the larger business by last-quarter revenue ($205.4M vs $125.2M, roughly 1.6× IMAX CORP). COLLEGIUM PHARMACEUTICAL, INC runs the higher net margin — 8.3% vs 0.5%, a 7.7% gap on every dollar of revenue. On growth, IMAX CORP posted the faster year-over-year revenue change (35.1% vs 12.9%). COLLEGIUM PHARMACEUTICAL, INC produced more free cash flow last quarter ($122.4M vs $28.0M). Over the past eight quarters, IMAX CORP's revenue compounded faster (25.8% CAGR vs 19.1%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
COLL vs IMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $125.2M |
| Net Profit | $17.0M | $637.0K |
| Gross Margin | 62.5% | 57.6% |
| Operating Margin | 29.6% | 19.3% |
| Net Margin | 8.3% | 0.5% |
| Revenue YoY | 12.9% | 35.1% |
| Net Profit YoY | 35.3% | -88.0% |
| EPS (diluted) | $0.48 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $205.4M | $125.2M | ||
| Q3 25 | $209.4M | $106.7M | ||
| Q2 25 | $188.0M | $91.7M | ||
| Q1 25 | $177.8M | $86.7M | ||
| Q4 24 | $181.9M | $92.7M | ||
| Q3 24 | $159.3M | $91.5M | ||
| Q2 24 | $145.3M | $89.0M | ||
| Q1 24 | $144.9M | $79.1M |
| Q4 25 | $17.0M | $637.0K | ||
| Q3 25 | $31.5M | $20.7M | ||
| Q2 25 | $12.0M | $11.3M | ||
| Q1 25 | $2.4M | $2.3M | ||
| Q4 24 | $12.5M | $5.3M | ||
| Q3 24 | $9.3M | $13.9M | ||
| Q2 24 | $19.6M | $3.6M | ||
| Q1 24 | $27.7M | $3.3M |
| Q4 25 | 62.5% | 57.6% | ||
| Q3 25 | 61.7% | 63.1% | ||
| Q2 25 | 57.7% | 58.5% | ||
| Q1 25 | 54.8% | 61.4% | ||
| Q4 24 | 54.0% | 52.2% | ||
| Q3 24 | 60.8% | 55.8% | ||
| Q2 24 | 62.5% | 49.4% | ||
| Q1 24 | 63.1% | 59.3% |
| Q4 25 | 29.6% | 19.3% | ||
| Q3 25 | 29.7% | 27.2% | ||
| Q2 25 | 18.7% | 15.6% | ||
| Q1 25 | 12.2% | 19.3% | ||
| Q4 24 | 20.9% | 10.3% | ||
| Q3 24 | 21.9% | 21.2% | ||
| Q2 24 | 32.7% | 3.2% | ||
| Q1 24 | 34.1% | 15.3% |
| Q4 25 | 8.3% | 0.5% | ||
| Q3 25 | 15.0% | 19.4% | ||
| Q2 25 | 6.4% | 12.3% | ||
| Q1 25 | 1.4% | 2.7% | ||
| Q4 24 | 6.9% | 5.7% | ||
| Q3 24 | 5.9% | 15.2% | ||
| Q2 24 | 13.5% | 4.0% | ||
| Q1 24 | 19.1% | 4.1% |
| Q4 25 | $0.48 | $0.02 | ||
| Q3 25 | $0.84 | $0.37 | ||
| Q2 25 | $0.34 | $0.20 | ||
| Q1 25 | $0.07 | $0.04 | ||
| Q4 24 | $0.36 | $0.09 | ||
| Q3 24 | $0.27 | $0.26 | ||
| Q2 24 | $0.52 | $0.07 | ||
| Q1 24 | $0.71 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $151.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $301.7M | $337.9M |
| Total Assets | $1.7B | $894.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $386.7M | $151.2M | ||
| Q3 25 | $285.9M | $143.1M | ||
| Q2 25 | $222.2M | $109.3M | ||
| Q1 25 | $197.8M | $97.1M | ||
| Q4 24 | $162.8M | $100.6M | ||
| Q3 24 | $120.0M | $104.5M | ||
| Q2 24 | $271.6M | $91.6M | ||
| Q1 24 | $318.0M | $81.0M |
| Q4 25 | $301.7M | $337.9M | ||
| Q3 25 | $274.8M | $349.5M | ||
| Q2 25 | $232.2M | $320.4M | ||
| Q1 25 | $234.4M | $299.5M | ||
| Q4 24 | $228.8M | $299.5M | ||
| Q3 24 | $234.3M | $289.4M | ||
| Q2 24 | $216.6M | $267.2M | ||
| Q1 24 | $222.2M | $258.8M |
| Q4 25 | $1.7B | $894.0M | ||
| Q3 25 | $1.6B | $889.6M | ||
| Q2 25 | $1.6B | $868.6M | ||
| Q1 25 | $1.6B | $848.3M | ||
| Q4 24 | $1.7B | $830.4M | ||
| Q3 24 | $1.6B | $847.6M | ||
| Q2 24 | $1.1B | $827.4M | ||
| Q1 24 | $1.1B | $824.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | $29.4M |
| Free Cash FlowOCF − Capex | $122.4M | $28.0M |
| FCF MarginFCF / Revenue | 59.6% | 22.3% |
| Capex IntensityCapex / Revenue | 0.3% | 1.1% |
| Cash ConversionOCF / Net Profit | 7.25× | 46.11× |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | $118.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $123.0M | $29.4M | ||
| Q3 25 | $78.4M | $67.5M | ||
| Q2 25 | $72.4M | $23.2M | ||
| Q1 25 | $55.4M | $7.0M | ||
| Q4 24 | $84.6M | $11.5M | ||
| Q3 24 | $-9.0M | $35.3M | ||
| Q2 24 | $67.4M | $35.0M | ||
| Q1 24 | $61.9M | $-11.0M |
| Q4 25 | $122.4M | $28.0M | ||
| Q3 25 | $78.3M | $64.8M | ||
| Q2 25 | $72.4M | $20.9M | ||
| Q1 25 | $54.6M | $5.3M | ||
| Q4 24 | $84.1M | $6.9M | ||
| Q3 24 | $-9.2M | $34.2M | ||
| Q2 24 | $67.1M | $33.5M | ||
| Q1 24 | $61.4M | $-12.1M |
| Q4 25 | 59.6% | 22.3% | ||
| Q3 25 | 37.4% | 60.7% | ||
| Q2 25 | 38.5% | 22.8% | ||
| Q1 25 | 30.7% | 6.1% | ||
| Q4 24 | 46.2% | 7.4% | ||
| Q3 24 | -5.8% | 37.3% | ||
| Q2 24 | 46.2% | 37.6% | ||
| Q1 24 | 42.3% | -15.3% |
| Q4 25 | 0.3% | 1.1% | ||
| Q3 25 | 0.1% | 2.6% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.4% | 1.9% | ||
| Q4 24 | 0.3% | 5.0% | ||
| Q3 24 | 0.2% | 1.2% | ||
| Q2 24 | 0.2% | 1.8% | ||
| Q1 24 | 0.4% | 1.4% |
| Q4 25 | 7.25× | 46.11× | ||
| Q3 25 | 2.49× | 3.27× | ||
| Q2 25 | 6.05× | 2.06× | ||
| Q1 25 | 22.92× | 2.99× | ||
| Q4 24 | 6.75× | 2.16× | ||
| Q3 24 | -0.96× | 2.54× | ||
| Q2 24 | 3.44× | 9.78× | ||
| Q1 24 | 2.23× | -3.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COLL
Segment breakdown not available.
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
